Therapeutic targeting of Bcl-2 family for treatment of B-cell malignancies

References

• Elson C, Jablonska KF, Taylor RB. Functional half-life of virgin and primed B lymphocytes. Eur J Immunol 1976;6:634-8
   Google Scholar
• Reed JC. Apoptosis-based therapies. Nat Rev Drug Discov 2002;1:111-21
   PubMed Web of Science ®Google Scholar
• Van Parijs L, Abbas AK. Homeostasis and Self-Tolerance in the Immune System: turning Lymphocytes off Science. 1998;280:243-8
   Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Herbst RS. To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 2008;118:1979-90
   PubMed Web of Science ®Google Scholar
• Plati J, Bucur O, Khosravi-Far R. Apoptotic cell signaling in cancer progression and therapy. Integr Biol (Camb) 2011;3:279-96
   PubMed Web of Science ®Google Scholar
• Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003;22:8590-607
   PubMed Web of Science ®Google Scholar
• Ke N, Godzik A, Reed JC. Bcl-B, a novel Bcl-2 family member that differentially binds and regulates Bax and Bak. J Biol Chem 2001;276:12481-4
   PubMed Web of Science ®Google Scholar
• Chipuk JE, Moldoveanu T, Llambi F, et al. The BCL-2 family reunion. Mol Cell 2010;37:299-310
   PubMed Web of Science ®Google Scholar
• Hetz C, Bernasconi P, Fisher J, et al. Proapoptotic BAX and BAK modulate the unfolded protein response by a direct interaction with IRE1alpha. Science 2006;312:572-6
   PubMed Web of Science ®Google Scholar
• Nikoletopoulou V, Markaki M, Palikaras K, Tavernarakis N. Crosstalk between apoptosis, necrosis and autophagy. Biochim Biophys Acta 2013;1833:3448-59
   PubMed Web of Science ®Google Scholar
• Tsujimoto Y, Finger LR, Yunis J, et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 1984;226:1097-9
   PubMed Web of Science ®Google Scholar
• Tsujimoto Y, Yunis J, Onorato-Showe L, et al. Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. Science 1984;224:1403-6
   PubMed Web of Science ®Google Scholar
• Monni O, Joensuu H, Franssila K, et al. Bcl-2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. Blood 1997;90:1168-74
   PubMed Web of Science ®Google Scholar
• Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005;102:13944-9
   PubMed Web of Science ®Google Scholar
• Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99:15524-9
   PubMed Web of Science ®Google Scholar
• Krajewski S, Bodrug S, Krajewska M, et al. Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol 1995;146:1309-19
   PubMed Web of Science ®Google Scholar
• Ionov Y, Yamamoto H, Krajewski S, et al. Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc Natl Acad Sci USA 2000;97:10872-7
   PubMed Web of Science ®Google Scholar
• Hanada M, Delia D, Aiello A, et al. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993;82:1820-8
   PubMed Web of Science ®Google Scholar
• Pepper C, Lin TT, Pratt G, et al. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 2008;112:3807-17
   PubMed Web of Science ®Google Scholar
• Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 2013;121:4021-31; quiz 250
   PubMed Web of Science ®Google Scholar
• Rantanen S, Monni O, Joensuu H, et al. Causes and consequences of BCL2 overexpression in diffuse large B-cell lymphoma. Leuk Lymphoma 2001;42:1089-98
   PubMed Web of Science ®Google Scholar
• Iqbal J, Meyer PN, Smith LM, et al. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clin Cancer Res 2011;17:7785-95
   PubMed Web of Science ®Google Scholar
• Hermine O, Haioun C, Lepage E, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin’s lymphoma. Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood 1996;87:265-72
   PubMed Web of Science ®Google Scholar
• Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin’s lymphoma. Blood 1997;90:244-51
   PubMed Web of Science ®Google Scholar
• Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993;81:151-7
   PubMed Web of Science ®Google Scholar
• Miyashita T, Reed JC. bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 1992;52:5407-11
   PubMed Web of Science ®Google Scholar
• Letai A, Bassik MC, Walensky LD, et al. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002;2:183-92
   PubMed Web of Science ®Google Scholar
• Moreau C, Cartron PF, Hunt A, et al. Minimal BH3 peptides promote cell death by antagonizing anti-apoptotic proteins. J Biol Chem 2003;278:19426-35
   PubMed Web of Science ®Google Scholar
• Reed JC, Pellecchia M. Apoptosis-based therapies for hematologic malignancies. Blood 2005;106:408-18
   PubMed Web of Science ®Google Scholar
• Pro B, Leber B, Smith M, et al. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol 2008;143:355-60
   PubMed Web of Science ®Google Scholar
• Campos L, Sabido O, Rouault JP, Guyotat D. Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood 1994;84:595-600
   PubMed Web of Science ®Google Scholar
• Hu Y, Bebb G, Tan S, et al. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer. Clin Cancer Res 2004;10:7662-70
   Google Scholar
• Nunez G, London L, Hockenbery D, et al. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 1990;144:3602-10
   PubMed Web of Science ®Google Scholar
• Durig J, Duhrsen U, Klein-Hitpass L, et al. The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia. Leukemia 2011;25:638-47
   Google Scholar
• Walensky LD, Bird GH. Hydrocarbon-stapled peptides: principles, practice, and progress. J Med Chem 2014;57:6275-88
   PubMed Web of Science ®Google Scholar
• Walensky LD, Kung AL, Escher I, et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 2004;305:1466-70
   PubMed Web of Science ®Google Scholar
• Dangl M CY, Lehmann C, Friess T. Synergistic anticancer activity of clinical stage, non-genotoxic apoptosis inducing agents RG7388 (MDM2 antagonist) and ABT-199 (GDC-0199, BCL2 inhibitor) in p53 wild-type AML tumor models. In: American Association for Cancer Research (AACR) Annual Meeting. San Diego, CA; 2014; 5505
   Google Scholar
• Pan R, Kojima K, Zheng Z, et al. Activation of p53 by novel MDM2 antagonist RG7388 overcomes AML inherent and acquired resistance to Bcl-2 inhibitor ABT-199 (GDC-0199). Blood 2014; abstract 2162
   Google Scholar
• Leone M, Zhai D, Sareth S, et al. Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res 2003;63:8118-21
   PubMed Web of Science ®Google Scholar
• Shelley MD, Hartley L, Groundwater PW, Fish RG. Structure-activity studies on gossypol in tumor cell lines. Anticancer Drugs 2000;11:209-16
   PubMed Web of Science ®Google Scholar
• Qui J, Levin LR, Buck J, Reidenberg MM. Different Pathways of Cell Killing by Gossypol Enantiomers. Exp Biol Med 2002;227:398-401
   Google Scholar
• Balakrishnan K, Wierda WG, Keating MJ, Gandhi V. Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2008;112:1971-80
   PubMed Web of Science ®Google Scholar
• Kitada S, Leone M, Sareth S, et al. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem 2003;46:4259-64
   PubMed Web of Science ®Google Scholar
• Zhai D, Jin C, Satterthwait AC, Reed JC. Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ 2006;13:1419-21
   PubMed Web of Science ®Google Scholar
• Wang G, Nikolovska-Coleska Z, Yang CY, et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem 2006;49:6139-42
   PubMed Web of Science ®Google Scholar
• Paoluzzi L, Gonen M, Gardner JR, et al. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood 2008;111:5350-8
   PubMed Web of Science ®Google Scholar
• Mohammad RM, Goustin AS, Aboukameel A, et al. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin Cancer Res 2007;13:2226-35
   PubMed Web of Science ®Google Scholar
• Varadarajan S, Vogler M, Butterworth M, et al. Evaluation and critical assessment of putative MCL-1 inhibitors. Cell Death Differ 2013;20:1475-84
   PubMed Web of Science ®Google Scholar
• Mohammad RM YD, Chen B, Aboukameel A, et al. ApoG2, a potent, non-toxic small-molecule inhibitor of Bcl-2 family: a preclinical trial in lymphoma. Cancer Res 2006;66:315
   Google Scholar
• Sun Y, Wu J, Aboukameel A, et al. Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo. Cancer Biol Ther 2008;7:1418-26
   PubMedGoogle Scholar
• Wei J, Stebbins JL, Kitada S, et al. BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem 2010;53:4166-76
   PubMed Web of Science ®Google Scholar
• Varadarajan S, Butterworth M, Wei J, et al. Sabutoclax (BI97C1) and BI112D1, putative inhibitors of MCL-1, induce mitochondrial fragmentation either upstream of or independent of apoptosis. Neoplasia 2013;15:568-78
   PubMed Web of Science ®Google Scholar
• Perciavalle RM, Stewart DP, Koss B, et al. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat Cell Biol 2012;14:575-83
   PubMed Web of Science ®Google Scholar
• Wang JL, Liu D, Zhang ZJ, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 2000;97:7124-9
   PubMed Web of Science ®Google Scholar
• Kazi A, Sun J, Doi K, et al. The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner. J Biol Chem 2011;286:9382-92
   PubMed Web of Science ®Google Scholar
• Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-81
   PubMed Web of Science ®Google Scholar
• Perez-Galan P, Roue G, Villamor N, et al. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 2007;109:4441-9
   PubMed Web of Science ®Google Scholar
• Konopleva M, Watt J, Contractor R, et al. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res 2008;68:3413-20
   PubMed Web of Science ®Google Scholar
• Basit F, Cristofanon S, Fulda S. Obatoclax (GX15-070) triggers necroptosis by promoting the assembly of the necrosome on autophagosomal membranes. Cell Death Differ 2013;20:1161-73
   PubMedGoogle Scholar
• Kim PS, Jochems C, Grenga I, et al. Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy. J Immunol 2014;192:2622-33
   PubMed Web of Science ®Google Scholar
• Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006;10:375-88
   PubMed Web of Science ®Google Scholar
• Kuroda J, Kimura S, Andreeff M, et al. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. Br J Haematol 2008;140:181-90
   PubMedGoogle Scholar
• Lin X, Morgan-Lappe S, Huang X, et al. ‘Seed’ analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 2007;26:3972-9
   PubMed Web of Science ®Google Scholar
• van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006;10:389-99
   PubMed Web of Science ®Google Scholar
• Chen J, Jin S, Abraham V, et al. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther 2011;10:2340-9
   PubMed Web of Science ®Google Scholar
• Park CM, Bruncko M, Adickes J, et al. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J Med Chem 2008;51:6902-15
   PubMed Web of Science ®Google Scholar
• Kaefer A, Yang J, Noertersheuser P, et al. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia. Cancer Chemother Pharmacol 2014;74:593-602
   Google Scholar
• Schoenwaelder SM, Jarman KE, Gardiner EE, et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 2011;118:1663-74
   PubMed Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013;19:202-8
   PubMed Web of Science ®Google Scholar
• O’Brien S, Moore JO, Boyd TE, et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2007;25:1114-20
   PubMed Web of Science ®Google Scholar
• O’Brien S, Moore JO, Boyd TE, et al. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol 2009;27:5208-12
   PubMed Web of Science ®Google Scholar
• Tilly H, Coiffier B, Michallet AS, et al. Phase I/II study of SPC2996, an RNA antagonist of Bcl-2, in patients with advanced chronic lymphocytic leukemia (CLL). J Clin Oncol 2007;25:7036
   Google Scholar
• Castro JE, Olivier LJ, Robier AA, et al. A phase II, open-label study of AT-101 in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2006;108; abstract 2838
   Google Scholar
• Schelman WR, Mohammed TA, Traynor AM, et al. A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer. Invest New Drugs 2014;32:295-302
   PubMed Web of Science ®Google Scholar
• Liu G, Kelly WK, Wilding G, et al. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res 2009;15:3172-6
   PubMed Web of Science ®Google Scholar
• Goard CA, Schimmer AD. An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies. Core Evid 2013;8:15-26
   PubMedGoogle Scholar
• Hwang JJ, Kuruvilla J, Mendelson D, et al. Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res 2010;16:4038-45
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Claxton DF, Crump M, et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009;113:299-305
   PubMed Web of Science ®Google Scholar
• Brown JR, Tesar B, Werner L, et al. Obatoclax in combination with fludarabine and rituximab (FR) is well-tolerated and shows promising clinical activity in relapsed CLL/SLL. Blood 2011;118; abstract 2865
   Google Scholar
• Wilson WH, O’Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010;11:1149-59
   PubMed Web of Science ®Google Scholar
• Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012;30:488-96
   PubMed Web of Science ®Google Scholar
• Kipps TJ, Wierda WG, Jones JA, et al. Navitoclax (ABT-263) plus fludarabine/cyclophosphamide/rituximab (FCR) or bendamustine/rituximab (BR): a phase 1 study in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Blood 2010;116; abstract 2455
   Google Scholar
• Eradat H, Grosicki S, Catalono J, et al. Preliminary results of a phase II open-label, randomized study of the BH3 mimetic protein navitoclax (ABT-263) with or without rituximab for treatment of previously untreated B-cell chroniclymphocytic leukemia. Blood 2012;120; abstract 190
   Google Scholar
• Seymour JF, Davids MS, Pagel JM, et al. ABT-199 (GDC-0199) in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: high response rates among patients with high-risk disease features including unmutated IGHV. Presented at the 19th Congress of the European Hematology Association 2014; abstract S702
   Google Scholar
• Roberts AW, Brander DM, Kipps TJ, et al. Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed/ Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood 2014;124: abstract 325
   Google Scholar
• de Vos S, Flowers CR, Wang D, et al. The Bcl-2 inhibitor ABT-199 (GDC-0199) in combination with bendamustine and rituximab in patients with relapsed or refractory non-Hodgkin’s lymphoma. Blood 2014;124; abstract 1722
   Google Scholar
• A study of GDC-0199 (ABT-199) plus MabThera/Rituxan (rituximab) compared with bendamustine plus MabThera/Rituxan (rituximab) in patients with relapsed or refractory chronic lymphocytic leukemia. Available from: http://www.clinicaltrials.gov/ct2/show/NCT02005471?term=NCT02005471&rank=1
   Google Scholar
• Flinn I, Brunvand M, Dyer MJS, et al. Preliminary results of a phase 1b study (GP28331) combining GDC-0199 (ABT-199) and obinutuzumab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia. Blood 2014;124; abstract 4687
   Google Scholar
• Seymour J, Roberts A, Stilgenbauer S, et al. Reduction of tumor lysis syndrome (TLS) risk in chronic lymphocytic leukemia (CLL patients treated with ABT-199 (GDC-0199): results of modifications to dosing schedule and TLS prophylaxis. Presented at the 19th Congress of the European Hematology Association 2014; Abstract P868
   Google Scholar
• Rooswinkel RW, van de Kooij B, Verheij M, Borst J. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B. Cell Death Dis 2012;3:e366
   PubMed Web of Science ®Google Scholar
• Yecies D, Carlson NE, Deng J, Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010;115:3304-13
   PubMed Web of Science ®Google Scholar
• Quinn BA, Dash R, Azab B, et al. Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs 2011;20:1397-411
   PubMed Web of Science ®Google Scholar
• Moreb JS, Schweder M. Human A1, a Bcl-2-related gene, is induced in leukemic cells by cytokines as well as differentiating factors. Leukemia 1997;11:998-1004
   PubMedGoogle Scholar
• Jamieson K, Odenike O. Late-phase investigational approaches for the treatment of relapsed/refractory acute myeloid leukemia. Expert Opin Pharmacother 2012;13:2171-87
   PubMed Web of Science ®Google Scholar
• Andreeff M, Konopleva M. Mechanisms of drug resistance in AML. Cancer Treat Res 2002;112:237-62
   Google Scholar
• Konopleva M, Milella M, Ruvolo P, et al. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia 2012;26:778-87
   PubMed Web of Science ®Google Scholar
• Zhang W, Ruvolo VR, Gao C, et al. Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells. Mol Cancer Ther 2014;13:1848-59
   PubMed Web of Science ®Google Scholar
• Li L, Pongtornpipat P, Tiutan T, et al. Potent efficacy of Bcl-2 inhibition with ABT-199 in high-risk aggressive B-lymphoma models when combined with knockdown of Mcl-1. Blood 2014;124: abstract 506
   Google Scholar
• Inoue K, Kohno T, Takakura S, et al. Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines. Leuk Res 2000;24:255-62
   PubMedGoogle Scholar
• Fox JL, Ismail F, Azad A, et al. Tyrosine dephosphorylation is required for Bak activation in apoptosis. EMBO J 2010;29:3853-68
   PubMed Web of Science ®Google Scholar
• Xin M, Li R, Xie M, et al. Small-molecule Bax agonists for cancer therapy. Nat Commun 2014;5:4935
   PubMed Web of Science ®Google Scholar
• Gavathiotis E, Reyna DE, Bellairs JA, et al. Direct and selective small-molecule activation of proapoptotic BAX. Nat Chem Biol 2012;8:639-45
   PubMed Web of Science ®Google Scholar
• Gu D, Wang S, Kuiatse I, et al. Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737. PLoS One 2014;9:e103015
   Google Scholar
• Kojima K, Konopleva M, Samudio IJ, et al. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML. Cell Cycle 2006;5:2778-86
   PubMed Web of Science ®Google Scholar
• Ruvolo PP, Deng X, May WS. Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia 2001;15:515-22
   PubMed Web of Science ®Google Scholar
• Tan N, Wong M, Nannini MA, et al. Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models. Mol Cancer Ther 2013;12:853-64
   PubMed Web of Science ®Google Scholar
• Perez-Galan P, Roue G, Lopez-Guerra M, et al. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Leukemia 2008;22:1712-20
   PubMed Web of Science ®Google Scholar
• Leung S, Miyake H, Zellweger T, et al. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. Int J Cancer 2001;91:846-50
   PubMed Web of Science ®Google Scholar
• Vandenberg CJ, Cory S. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 2013;121:2285-8
   PubMed Web of Science ®Google Scholar
• Gu J, Linnoila RI, Seibel NL, et al. A study of myc-related gene expression in small cell lung cancer by in situ hybridization. Am J Pathol 1988;132:13-17
   Google Scholar
• Slavc I, Ellenbogen R, Jung WH, et al. myc gene amplification and expression in primary human neuroblastoma. Cancer Res 1990;50:1459-63
   PubMedGoogle Scholar
• Lin B, Kolluri SK, Lin F, et al. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 2004;116:527-40
   PubMed Web of Science ®Google Scholar
• Mohan HM, Aherne CM, Rogers AC, et al. Molecular pathways: the role of NR4A orphan nuclear receptors in cancer. Clin Cancer Res 2012;18:3223-8
   PubMed Web of Science ®Google Scholar
• Muchmore SW, Sattler M, Liang H, et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 1996;381:335-41
   PubMed Web of Science ®Google Scholar
• Liu X, Dai S, Zhu Y, et al. The structure of a Bcl-xL/Bim fragment complex: implications for Bim function. Immunity 2003;19:341-52
   PubMed Web of Science ®Google Scholar
• Lee EF, Czabotar PE, Smith BJ, et al. Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family. Cell Death Differ 2007;14:1711-13
   PubMed Web of Science ®Google Scholar